Trump, Hegseth, and the High-T Gamble: When Military Readiness Meets Government Overreach

The Trump administration's new policy requiring annual testosterone screenings for military personnel aged 30 and older raises an important question: **How much of our biology should the government monitor in the name of readiness?**¹

Defense Secretary Pete Hegseth says the policy is designed to ensure troops have the "right testosterone levels" to maximize physical and mental readiness. Troops diagnosed with testosterone deficiency may choose testosterone replacement therapy (TRT), while those under 30 may volunteer for screening.¹

No reasonable person disputes that men with clinically diagnosed hypogonadism should have access to appropriate medical treatment. The real issue is whether routinely screening an entire age group of service members is justified by the scientific evidence.

At present, the answer is far from clear.

Clinical practice guidelines support TRT for men with confirmed testosterone deficiency and symptoms—not routine screening of otherwise healthy men.² Research shows TRT can improve muscle mass, strength, libido, and quality of life in men with true hypogonadism. However, studies have generally found only modest improvements in physical performance and little evidence that widespread TRT would substantially improve combat readiness across an entire military force.³

If the expected benefits are modest, then the policy deserves closer scrutiny.

The military already requires vaccinations, physical fitness tests, hearing exams, vision tests, and numerous other health assessments. Those requirements are part of military service. But every expansion of government access to personal medical information should still be examined carefully.

Hormone levels are deeply personal medical data.

Today the justification is readiness. Tomorrow it could be genetic markers, continuous biometric monitoring, neurological scans, or other biological measurements—all defended as tools to optimize performance. History shows that governments rarely give up powers once they acquire them.

This concern is why George Orwell's Nineteen Eighty-Four and Aldous Huxley's Brave New World remain relevant. Neither novel predicts America's future. Rather, both warn that freedom can erode gradually as governments normalize increasingly intrusive forms of oversight. Comparing today's Pentagon to Orwell's fictional dictatorship would be inaccurate. But dismissing every privacy concern simply because the stated purpose is military readiness would be equally unwise.

President Donald Trump, as Commander in Chief, bears political responsibility for the policies adopted by his administration. Whether this initiative originated with Secretary Hegseth or elsewhere within the Department of Defense, the administration should explain why expanding the collection of sensitive medical information is warranted when the available evidence suggests relatively modest gains.

Civil liberties should not depend on which political party controls the White House.

If Americans are skeptical when one administration expands government authority, they should be equally skeptical when another does the same. Protecting privacy is not a partisan principle—it is a constitutional one.

Treat genuine medical conditions. Absolutely.

But before normalizing another layer of government oversight into the private biology of those who serve, the administration should demonstrate that the benefits clearly outweigh the costs—not only in dollars, but in privacy, trust, and the precedent such policies establish.

Works Cited

1. Associated Press. "Hegseth Announces New Policy to Test Troops for Low Testosterone." Associated Press, 16 July 2026. .

2. Bhasin, Shalender, et al. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." The Journal of Clinical Endocrinology & Metabolism, vol. 103, no. 5, 2018, pp. 1715–1744. .

3. Nindl, Bradley C., et al. Research on testosterone and operational performance during military training indicates TRT may help men with true deficiency or temporary hormonal suppression but does not establish that broad screening significantly improves force-wide readiness. See also Endocrine Society, "Testosterone Therapy for Hypogonadism." .